Tesla Is the Least Trusted EV in the U.S., Survey Finds
According to the survey, just 26% of participants have a somewhat or very positive view of Tesla—significantly outweighed by the 39% plurality who have a somewhat or very negative view of the company. That leaves Tesla underwater on perception, scoring -13 in net positive view. To give you an idea of just how quickly the company is tanking its reputation, the same report found in April that Tesla had a net positive perception of -7, so that has nearly doubled in just a couple of months.
The situation actually gets worse when the report considers the 'intensity score,' which compares the number of people who feel strongly in either direction. There, Tesla sinks further to a score of -16. Basically, of the people who have strong views about Tesla, the hate greatly outweighs the love.
On trust, the water keeps on rising over Tesla's head. While 40% of survey participants said they somewhat trust or trust the brand a lot, 48% fell on the opposite side of the spectrum, either somewhat distrusting or distrusting the company a lot. That gives Tesla a net trust score of -8, by far the worst of any major EV company. In fact, the only other company to finish with a negative trust score is Vinfast, a Vietnamese automaker that couldn't find its footing in the American market.
Just as with perception, Tesla's trust issues get worse when zooming in on the people with the strongest opinions. Tesla's trust rating drops to -19 when comparing those who trust Tesla a lot versus those who distrust the company a lot.
Tesla's problems run deep, too. The company has a knack for capturing headlines—in part thanks to the media magnet that is CEO Elon Musk—but that really works against you when your vehicles are involved in high-profile accidents or embarrassing failures, like the Tesla Robotaxi launch in Austin, Texas. To that end, Tesla now has the lowest perceived safety rating of any major EV, per the report, with 55% of people viewing the company's cars as safe.
A big driver of the low safety score is Tesla's self-driving functionality, which simply does not have many fans among those who prefer not to be involved in fiery crashes. The report found that 53% of respondents believe robotaxis should be outlawed, and 55% believe Tesla's Full Self-Driving technology should be illegal.
All of that seems to fall in line with the fact that Tesla sales have been dropping precipitously over the last several months, even as Musk claims he's back to focusing on the company (when forming a new political party doesn't steal away his attention). But aside from all that, everything is going great!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) ('Sana'), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an underwritten public offering of $75.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Sana intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be sold by Sana. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen are acting as joint book-running managers for the proposed offering. The proposed offering is being made pursuant to a Registration Statement on Form S-3, including a base prospectus, previously filed with and declared effective by the SEC, and Sana will file a preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering, copies of which can be accessed for free through the SEC's website at When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the proposed offering may also be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@ Goldman Sachs & Co. LLC, Attn: Prospectus Department, at 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at prospectus-ny@ BofA Securities, Attn: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001 or by email at or TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846 or by email at This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of any such state or jurisdiction. About Sana Biotechnology Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. Sana has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements about Sana Biotechnology, Inc. (the 'Company,' 'we,' 'us,' or 'our') within the meaning of the federal securities laws, including those related to the completion, timing, and size of the proposed offering and our intent to grant the underwriters a 30-day option to purchase additional shares. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: whether or not we will be able to raise capital through the sale of securities or consummate the offering; the final terms of the offering; the satisfaction of customary closing conditions; prevailing market conditions; general economic and market conditions as well as geopolitical developments; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled 'Risk Factors' in documents that we file from time to time with the Securities and Exchange Commission, including the registration statement and the preliminary prospectus supplement relating to the proposed public offering. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations & Media: Nicole in to access your portfolio
Yahoo
18 minutes ago
- Yahoo
Informa TechTarget to Announce Q2 2025 Financial Results on August 12, 2025
Live Conference Call and Webcast Scheduled to Begin at 8:30 a.m. ET on August 12, 2025 NEWTON, Mass., August 06, 2025--(BUSINESS WIRE)--TechTarget, Inc. (Nasdaq: TTGT) ("Informa TechTarget" or the "Company"), a leading growth accelerator for the B2B Technology sector, today announced that it will release its Q2 2025 financial results for the three months ended June 30, 2025 before the market opens on Tuesday, August 12, 2025. The Company's Chief Executive Officer, Gary Nugent, and Chief Financial Officer, Dan Noreck, will host a live conference call and webcast at 8:30 a.m. Eastern Time on that day to discuss the Company's financial results and outlook. The Q2 2025 financial results will be available prior to the conference call and webcast on the investor relations section of the Company's website at Conference Call Dial-In Information: United States (Toll Free): 1-833-470-1428 United States: 1-404-975-4839 United Kingdom (Toll Free): +44 808 189 6484 United Kingdom: +44 20 8068 2558 Global Dial-in Numbers Access code: 967110 Please access the call at least 10 minutes prior to the time the conference is set to begin. Please ask to be joined into the Informa TechTarget call. Conference Call Webcast Information: This webcast can be accessed via Informa TechTarget's website at Conference Call Replay Information: A replay of the conference call will be available via telephone beginning one (1) hour after the conference call through September 11, 2025 at 11:59 p.m. ET. To hear the replay: United States (Toll Free): 1-866-813-9403 United States: 1-929-458-6194 Access Code: 703085 A web version will also be available for replay during the same period on Informa TechTarget's website at About Informa TechTarget TechTarget, Inc. (Nasdaq: TTGT), which also refers to itself as Informa TechTarget, informs, influences and connects the world's technology buyers and sellers, helping accelerate growth from R&D to ROI. With a vast reach of over 220 highly targeted technology-specific websites and over 50 million permissioned first-party audience members, Informa TechTarget has a unique understanding of and insight into the technology market. Underpinned by those audiences and their data, we offer expert-led, data-driven, and digitally enabled services that have the potential to deliver significant impact and measurable outcomes to our clients: Trusted information that shapes the industry and informs investment Intelligence and advice that guides and influences strategy Advertising that grows reputation and establishes thought leadership Custom content that engages and prompts action Intent and demand generation that more precisely targets and converts Informa TechTarget is headquartered in Boston, MA and has offices in 19 global locations. For more information, visit and follow us on LinkedIn. © 2025 TechTarget, Inc. All rights reserved. All trademarks are the property of their respective owners. View source version on Contacts Investor Inquiries Daniel NoreckMitesh KotechaInforma TechTarget617-431-9200investor@ Media Inquiries Garrett MannCorporate CommunicationsInforma
Yahoo
18 minutes ago
- Yahoo
Corteva raises annual profit forecast after strong first-half performance
(Reuters) -U.S. agrichemicals company Corteva raised its annual adjusted profit forecast on Wednesday, following strong performance in the first half of the year. Reuters had reported in May that U.S. farmers have hit very few snags with corn planting this spring, and the foreseeable future is barrier-free. Corteva's net sales rose 5.6% to $6.46 billion during the second quarter, driven by higher sales in all its regions. The company is among the largest crop-protection product makers in the United States, competing with the likes of Syngenta and German firms BASF and Bayer in the agricultural chemicals sector. The company raised its forecast for full-year adjusted earnings to be between $3.00 to $3.20 per share, from a prior view of $2.70 to $2.95 per share.
